Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 21, 2013

View Archived Issues

SUVN-A60203 and its effects on alcohol consumption

Researchers identify a novel mutation in the HEXB gene associated with Sandhoff disease

Vertex sells Incivo royalty rights to Janssen Pharmaceutica

Start-up company Viteava executes license for EGCG analogues and derivatives

Innate Pharma initiates program to develop anti-MICA antibody

Jacobus Pharmaceutical presents novel and potent antimalarial agent

Shionogi patents novel Na(v)1.7 channel blockers for pain

Inovio reports preclinical findings on DNA vaccine for MERS-CoV

Galapagos' subsidiary signs drug discovery collaboration with Boehringer Ingelheim

Novartis presents new DGAT1 inhibitors

FDA accepts Omidria as brand name for OMS-302

Researchers in Japan divulge novel PDE2A inhibitors for schizophrenia

Simeprevir approved in Canada for chronic HCV infection

Novel serpin C1 inhibitors prepared by Alnylam Pharmaceuticals

CytRx begins phase II trial of aldoxorubicin in glioblastoma multiforme

Presidio Pharmaceuticals reports novel NS5B inhibitors for HCV infection

European approval of Kineret for CAPS

Clovis Oncology gains rights to lucitanib through acquisition of EOS

Vect-Horus signs collaboration agreement with Advanced Accelerator Applications

Illumina receives FDA premarket clearances

Pfizer launches Vindaqel in Japan

F-star generates an Fcab antibody against HER2

DS-3078 evaluated in first-in-human advanced solid tumors study

Kyowa Hakko Kirin identifies lead compound for colon cancer

FDA issues complete response letter for cariprazine

Canadian launch for Jetrea

FDA committee recommends approval of Vimizim for mucopolysaccharidosis type IVA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...